K102214 Page 10+3

510(k) Summary

Page 1 of 3 9-Dec-10

DEC 1 6 2010

Company

Crospon Ltd.

Galway Business Park

Dangan

Galway, Ireland

Tel – 011 [353] (91) 519882 Fax – 011 [353] (91) 519873

Official Contact:

John O'Dea PhD

Proprietary or Trade Name:

EndoFLIP®

Common/Usual Name:

Gastrointestinal motility monitoring system

Classification / CFR:

FFX / CFR 876.1725

Device:

EndoFLIP® System and Catheter

Predicate Devices:

K092850 - Crospon - EndoFLIP®

Device Description:

The EndoFLIP® comprises a measuring system and a single use catheter to assist in measuring the gastric sleeve. In practice, the EndoFLIP® balloon catheter is attached to a syringe, pre-filled with a diluted saline solution, which is inserted into the syringe pump on the front of the EndoFLIP® system. The deflated balloon is inserted into the stomach by an anesthesiologist with placement being confirmed by the surgeon under direct laparoscopic visualization. Once the balloon has been correctly located, it is then inflated with the diluted saline solution to a user programmed volume. The display estimates the gastric sleeve diameter at sixteen points along the balloon. The system also allows snapshots to be taken and compared to real-time images.

Indications for Use:

The EndoFLIP® EF-620 catheter is indicated for use as an adjunct to a bougie for measuring the size of a gastric sleeve created during bariatric surgery. It is suitable for diameter measurements for 22 to 60 French sleeves.

The EF-620 catheter is to be used only with the EndoFlip System.

Patient Population:

Patients undergoing bariatric surgery

Environment of Use:

Hospitals and Surgery Centers

Contraindications:

The EndoFLIP® System is contraindicated where endoscopy is

contraindicated.

510(k) SummaryPage 2 of 3 9-Dec-10

Device Attributes:

Design	
Principle of Operation	Syringe pump device that targets an inflate volume within a balloon inserted into the lumen of an organ. Provides an Estimated Diameter (D _{est}) of the balloon at 16 points along its length when inflated with custom conductive solution.
	D _{est} electrodes are located at 16 points along the catheter inside a balloon.
Energy Used And/Or Delivered	No electrical energy is delivered into the patient
Human Factors	Specified for 20 to 40°C operating environment
•	Touch screen user interface
	On screen keypad and external keypad interface provided
Data Recording	Data is saved internally and can be exported to a USB mass storage device or printed to an attached USB printer
Electrical Safety	IEC60601-1 2nd Ed. + Am.1 + Am.2 .
Mechanical Safety	Travel limits are detected by mechanical switches
	Syringe is automatically put in its home position at power on
	Maximum volume is set by the volume of solution in the syringe
•	which is factory filled. This volume matches the balloon size on the
	catheter. The Balloon Inflate Volume cannot be set above the
,	factory set syringe volume.
	The Deflate button is available after inflation has commenced.
	The syringe can be manually retracted at any time.
	Rigid syringe used to avoid potential volume errors
	Stepper motor driven lead screw is used to maintain accurate
	control over the syringe piston position. Piston movement
	resolution is 0.003175 mm (one step)
CI 10 04	No calibration required
Chemical Safety	Conductive solution inside balloon is diluted saline
Thermal Safety	Internal cooling fan with enclosure temperature monitoring. Alarm if temperature exceeds limits.
Biocompatibility	All materials have passed biocompatibility tests in accordance with ISO 10993-1
Compatibility With The	EndoFLIP operates with custom catheters only
Environment And Other	
Devices .	
Sterility	Accessories are supplied non-sterile and are single patient use
, Performance	EndoFLIP ® passed the performance testing:
	Estimated balloon diameter (D _{est}) at 16 points in the balloon,
	displayed in numeric and graphical form
	Range: 7 to 20 mm
	Resolution: 0.1 mm
	Accuracy: ± 1mm (at 95% confidence) rounded to nearest integer

K102214 Page 3 of 3

510(k) Summary Page 3 of 3 9-Dec-10

Substantial Equivalence:

The EndoFLIP® system with EF-620 catheter is viewed as substantially equivalent to the predicate device because:

Indications:

Similar to predicate – K092850 – Crospon EndoFLIP® system with catheter measure the diameter of the stoma during gastric band procedures while the proposed indication of the EndoFLIP® EF-620 catheter is for use in measuring the size of a gastric sleeve created during bariatric surgery.

Technology:

Identical technology to predicate - K092850 - Crospon EndoFLIP® system with catheter

Both catheters can only be used with the predicate EndoFLIP® controller and the construction and materials of the new catheter are identical to the predicate.

Materials:

The materials in contact with the patient are identical to predicate device K092850 – Crospon EndoFLIP® system with catheter.

Environment of Use:

Identical to predicate - K092850 - Crospon EndoFLIP® system with catheter

Patient Population:

Identical to predicate - K092850 - Crospon EndoFLIP® system with catheter

Comparative Performance and Specifications:

We performed the appropriate bench testing to demonstrate that the new catheter in combination with the EndoFLIP® controller performs within the specifications of the predicate catheter with the EndoFLIP® controller.

Therefore one can find that the EndoFLIP® system with new catheter and the new indications for use are viewed as substantially equivalent to the predicate device.

DEPARTMENT OF HEALTH & HUMAN SERVICES



Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002

Crospon, Ltd. c/o Mr. Paul E. Dryden President and Regulatory Consultant ProMedic, Inc. 24301 Woodsage Drive BONITA SPRINGS FL 34134-2958

DEC 1 6 2070

Re: K102214

Trade/Device Name: EndoFLIP® System Regulation Number: 21 CFR §876.1725

Regulation Name: Gastrointestinal motility and monitoring system

Regulatory Class: II Product Code: FFX

Dated: December 9, 2010 Received: December 10, 2010

Dear Mr. Dryden:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related

adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21) CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Herbert P. Lerner, M.D., Director (Acting)

Division of Reproductive, Gastro-Renal

and Urological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

510(k) Number:

K102214

Device Name:

EndoFLIP® System

Indications for Use:

The EndoFLIP® EF-620 catheter is indicated for use as an adjunct to a bougie for measuring the size of a gastric sleeve created during bariatric surgery. It is suitable for diameter measurements for 22 to 60 French sleeves.

The EF-620 catheter is to be used only with the EndoFlip System.

Prescription Use XX (Part 21 CFR 801 Subpart D)

Over-the-counter use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)

Division of Reproductive, Gastro-Renal, and Urological Devices

510(k) Number.